TD Cowen on Royalty Pharma (RPRX): BIIB Ph2 results 'de-risks upside potential for royalty'
Tweet Send to a Friend
TD Cowen analyst Steve Scala reiterated a Buy rating and $50.00 price target on Royalty Pharma (NASDAQ: RPRX)The analyst commented ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
